2

Leg-lengthening surgery changed my life. It cost $27,000 but I'm 5 inches taller...

 1 year ago
source link: https://finance.yahoo.com/news/leg-lengthening-surgery-changed-life-090000440.html
Go to the source link to view the article. You can view the picture content, updated content and better typesetting reading experience. If the link is broken, please click the button below to view the snapshot at that time.

Leg-lengthening surgery changed my life. It cost $27,000 but I'm 5 inches taller and I feel more charismatic.

Sam Tabahriti
Tue, January 10, 2023, 1:05 AM GMT+9·5 min read
Ibrahim Alğan, in a wheelchair after surgery, right, and sitting outside after one of his surgeries. He paid nearly $30,000 to make his legs longer with surgery.
Ibrahim Alğan, in a wheelchair after surgery, right, and outside after one of his operations. He paid nearly $27,000 for surgery to make his legs longer.Courtesy of Wannabetaller
  • Ibrahim Alğan paid $26,850 for surgery to make his legs longer.

  • The 30-year-old told Insider he hated being short. "When you're short, you start 1-0 down."

  • After his leg-lengthening surgery, Alğan founded a Turkey-based clinic offering the same procedure.

As a school counselor, Ibrahim Alğan's job was to help young people solve their problems. Yet he couldn't solve his own: a serious height complex.

Alğan, who's 30, is from the city of Adana in southern Turkey. He was 5-foot-2 and had strong feelings about his height.

"If you're shorter, people don't take you as seriously as a tall person," he told Insider. He said he felt he wasn't confident enough to help students at his school.

"I strongly believe that charisma is one of the must-have features in leadership," he said. "When you're short, you start 1-0 down."

Alğan said his colleagues made jokes about his height at least once a week. He said he felt tall people around him were more popular and had more opportunities. "They were more advantageous in both private relationships and recruitment," he said.

He said he'd never forgotten his first girlfriend telling him she wished he was taller, and said derogatory comments throughout his life "have always remained" like "a wound in me."

So he researched methods that claim to help a person grow taller. He took powders and pills to increase his height. He played basketball, swam, and jumped.

"I used to hang from a bar minutes before going to sleep almost every night," he said. "I used reflexological insoles that claimed to stimulate height increase."

Nothing worked, except for shoes with hidden heels that made him up to 3 inches taller. But they weren't enough. "It was like a false dream," he said. "Every time I took off my shoes, I was facing reality again.

"My obsession was getting bigger every day."

'My life purpose'

Ibrahim Alğan is laying in a hospital bed before his surgery.
Ibrahim Alğan is laying in a hospital bed before his surgery.


Alğan had his first operation in February 2015.Courtesy of Wannabetaller

After two rounds of leg-lengthening surgery, Alğan added 5 inches to his height.

Alğan was 5-foot-2 before his leg-lengthening surgery.

Recommended Stories
  • 3d051e424dbee4ac9bf6a8f63ccf8dae.cf.webp
    TechCrunch

    Microsoft acquires Fungible, a maker of data processing units, to bolster Azure

    In December, reports suggested that Microsoft had acquired Fungible, a startup fabricating a type of data center hardware known as a data processing unit (DPU), for around $190 million. Today, Microsoft confirmed the acquisition but not the purchase price, saying that it plans to use Fungible's tech and team to deliver "multiple DPU solutions, network innovation and hardware systems advancements." "Fungible’s technologies help enable high-performance, scalable, disaggregated, scaled-out data center infrastructure with reliability and security," Girish Bablani, the CVP of Microsoft's Azure Core division, wrote in a blog post.

    9h ago
  • 51a5ae1dcfb06c67eac4f4b86be3e47d.cf.webp
    Robb Report

    Elvis Presley’s Dilapidated Private Jet Sat in the Desert for 40 Years. It Just Sold for $260,000.

    Noting her husband's love of winged transport, Priscilla Presley spoke about the King's aircraft collection at the auction.

    12h ago
  • d9dda274226cc6bcdb9cb8e463ff5bd2.cf.webp
    Decrypt Media

    Bankrupt Voyager Locks Horns With Alameda as SEC Questions $1B Binance Deal

    Both the SEC and Alameda Research, once a creditor one of Voyager’s creditors, have questioned the legal underpinnings of the proposed deal.

    15h ago
  • 1f5a7afde75817f205c0d2a7b990ce7a.cf.webp
    American City Business Journals

    Editas lays off 60, stops work on cancer, retinal disease

    The Cambridge gene-editing company is laying off 20% of its workforce as it cuts drug programs geared toward retinal diseases and solid tumors.

    9h ago
  • 420fe3e2c6f383c95d72dc2e3258c972.cf.webp
    MarketWatch

    CVS eyes next-generation health clinics after Amazon’s move for One Medical

    CVS Health Corp. is investing in a young chain of health clinics, and may be looking to acquire another.

    3h ago
  • 88c5b382e5e9e4ea852e01bfc1435a7b.cf.webp
    Zacks

    Biogen (BIIB), Eisai's Lecanemab Gets FDA Nod for Alzheimer's

    FDA approves Biogen (BIIB) and Eisai's lecanemab on an accelerated basis. Eisai filed a supplemental biologics license application (sBLA) to the FDA to get a traditional approval for Leqembi.

    13h ago
  • 3285bad383eab05c18373adc7275cbc8.cf.webp
    Barrons.com

    It’s Pharma Time: Why Merck and Lilly Are Buys, but Not Pfizer.

    With rates rising, biotech has faded. Investors have favored the pharma stalwarts. Bank of America’s drug analyst Geoff Meacham runs through the one’s to watch and a few to avoid. Plus: Could it be another banner year for Devon Energy?

    1d ago
  • 052eef2e7ea8660a4c9ae1e0a7abffae.cf.webp
    MarketWatch

    Pfizer’s Paxlovid will not be included in China’s national insurance

    Chinese health care authorities declined to include Pfizer's COVID-19 treatment drug in a national reimbursement list that would have allowed patients to get it at a cheaper price throughout the country, saying it was too expensive.

    43m ago
  • 8da4fcfd8edd526d29212fc6906834cd.cf.webp
    CNW Group

    PanGenomic Health to Launch E-Commerce Platform for Personalized Natural Health

    PanGenomic Health Inc. ("PanGenomic Health" or the "Company") (CSE: NARA) is pleased to announce that it plans to launch its e-commerce platform for personalized natural health solutions this month. Built as an extension to its Nara consumer app and website launched in 2022, the e-commerce platform on nara.care will market its proprietary natural herbal remedy information library and practitioner-vetted brands. At launch, the Company plans to market its offering online in North America, with exp

    16h ago
  • 96d076434b2a015a3010bd2787b8c856.cf.webp
    MarketWatch

    CureVac shares surge after preliminary data on COVID-19 and flu shots

    CureVac shares rocketed 26% in premarket trade as the German company said preliminary data from its early stage trial for its COVID-19 and seasonal flu shots had positive results to advance to the next stage of clinical testing. CureVac is developing the shots with GlaxoSmithKline . CureVac said the COVID-19 shot was well tolerated, and that neutralizing antibodies were beginning at the lowest tested dose for younger adults. The seasonal flu shot was also well tolerated with an increase in antib

    18h ago
  • 006a33b84ed2e431dc3b55d90537cf50.cf.webp
    Reuters

    Eisai, Biogen's Alzheimer's drug price should not dent demand - analysts

    The price set by the companies is higher than some analyst estimates of about $20,000. "As a result of this higher than expected pricing, we think it is reasonable to see peak sales reach $15.2 billion worldwide," BMO analyst Evan Seigerman said in a research note. However, the price tag is lower than that of Eisai and Biogen's first Alzheimer's disease drug, Aduhelm, which was initially priced at $56,000 annually before the drugmakers halved the price amid controversy over its approval.

    15h ago
  • c95a47ecd86cf453261c49070d9fd0c2.cf.webp
    American City Business Journals

    Ipsen to buy liver disease drugmaker for $952M

    Ipsen is set to acquire Albireo Pharma Inc., the rare liver disease-focused biopharma spun out of AstraZeneca in 2008, for about $952 million.

    12h ago
  • d777a3467505f418cf8336dab3c10d76.cf.webp
    Fortune

    China still hasn’t approved any mRNA vaccines—but a new homegrown Omicron booster could break through Beijing’s barriers

    Chinese officials say they have "safe and effective" vaccines as Beijing rebuffs mRNA shots from the U.S. and the EU.

    18h ago
  • e693c7a440af087400d7a864b293dd77.cf.webp
    Motley Fool

    2 Healthcare Stocks That Could Make You Richer

    While the healthcare industry may not seem at first glance like the most exciting place to invest your cash, it has proven to be one of the most resilient sectors for investing. Healthcare companies tend to supply the products and services that consumers need no matter what is happening with the market or the economy. If you are looking to add cash to more fantastic healthcare stocks in the month of January, here are two no-brainer buys that can enrich your portfolio over the long term.

    2d ago
  • 5ed3b4ae70e8a1636e49f29983411c8f.cf.webp
    CNW Group

    MindMed Provides Corporate Update and 2023 Outlook

    Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today provided a corporate update and outlook for 2023.

    16h ago
  • 9a02088a16f899bd2de4dfcf61cdb40a.cf.webp
    Benzinga

    Israel Based Study Shows Omicron Adapted Vaccine Shots Cut Hospitalization Rates In Elderly

    Israel based real-world study shows that omicron-targeted COVID-19 vaccine from Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) reduced hospitalizations among older patients. The study has not yet been peer-reviewed. Data exhibited an 81% reduction in hospitalizations among people aged 65 and older who had received the booster against those who had previously received at least two COVID vaccinations but not the omicron-adapted shot. Related: FDA Authorizes Pfizer/BioNTech And Moderna's Biv

    10h ago
  • 831eb9ead911cb8ab39ae56dacdef364.cf.webp
    Fox News

    Nearly 90% of people in one of China's most populous provinces infected with COVID: report

    Almost 90% of residents in China's Henan province, the third most populous in China, were infected with COVID-19 as of Jan. 6, according to a Chinese official.

    8h ago
  • 88c5b382e5e9e4ea852e01bfc1435a7b.cf.webp
    Zacks

    Alnylam (ALNY) Posts Strong Preliminary Revenues for 4Q & FY22

    Alnylam (ALNY) reports strong preliminary product revenues for its marketed drugs, Onpattro, Amvuttra, Givlaari and Oxlumo for the fourth quarter and full year of 2022.

    10h ago
  • 1f285427f3309c4dda25fcf2034e2f63.cf.webp

    Why Ultra-Processed Foods Are So Bad for You

    Recent research finds that highly processed food may pose health risks.

    11h ago
  • f8706505ea3c5f628205f23e35bfc70d.cf.webp
    Motley Fool

    3 Breakout Growth Stocks to Buy for the Long Haul

    Belite Bio (NASDAQ: BLTE), TransMedics Group (NASDAQ: TMDX) and Rhythm Pharmaceuticals (NASDAQ: RYTM) set themselves apart over the past year with triple-digit share price gains. Each of the healthcare companies is developing something unique, whether it be finding treatments for maladies with no approved treatments, a more effective way to do organ transplants, or a more precise way to treat disorders that lead to obesity. Belite Bio is a clinical-stage biopharmaceutical company that focuses on therapies to treat blindness, diabetes, and liver disease.

    15h ago

About Joyk


Aggregate valuable and interesting links.
Joyk means Joy of geeK